Company Name, Ticker, Customers, else..

Fulcrum Therapeutics Inc (NASDAQ: FULC)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Fulcrum Therapeutics Inc 's

Name: Fulcrum Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

FULC Sales vs. its Competitors Q1 2026

Comparing the current results to its competitors, Fulcrum Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.1 %, recorded in the same quarter.

• List of FULC Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Fulcrum Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 28.34 %

<< FULC Stock Performance Comparisons

Fulcrum Therapeutics Inc 's Comment on Competition and Industry Peers

The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies and intense competition. Its competitors include major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company is developing product candidates for sickle cell disease (SCD), focusing on small molecule oral therapies designed to increase HbF levels. The competitive landscape includes existing therapies and new product candidates from other developers. The company also faces risks related to patent protection and intellectual property rights that may impact its competitive position.

<< See the full list of FULC competitors

*Market share is calculated based on total revenue.

FULC's Stock Performance relative to its Competitors

Publicly Traded Peers of Fulcrum Therapeutics Inc

Esperion Therapeutics Inc
Share Performance

-14.29%

This Year

Esperion Therapeutics Inc

Profile

Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.

More about Esperion Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 799.303 mill.	$ 418.244 mill.	$ -7.423 mill.

Mineralys Therapeutics Inc
Share Performance

+8.50%

30 Days

Mineralys Therapeutics Inc

Profile

Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.

More about Mineralys Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,486.746 mill.	$ - mill.	$ -349.576 mill.

Medicure Inc
Share Performance

0.00%

One Year

Medicure Inc

Profile

Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.

More about Medicure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 25.925 mill.	$ -5.920 mill.

Moderna Inc
Share Performance

+131.05%

30 Days

Moderna Inc

Profile

Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.

More about Moderna Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 58,549.780 mill.	$ 2,228.000 mill.	$ -3,151.000 mill.

Neurogene Inc
Share Performance

+78.57%

This Year

Neurogene Inc

Profile

The company develops genetic medicines targeting rare neurological diseases and is currently in clinical stages.

More about Neurogene Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 811.873 mill.	$ - mill.	$ -111.110 mill.

61 more competitors available

Sources: Fulcrum Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 11, 2026 6:47 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fulcrum Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.